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The Epstein-Barr virus (EBV) ~  is a human lymphotropic herpes virus associated 
with Burkitt's lymphoma (BL) and nasopharyngeal carcinoma (1, 2). EBV is also 
known  to  cause  infectious  mononucleosis  (3).  It  converts  normal  human  B 
iymphocytes to immortalized lymphoblastoid lines. In vitro primary infection is 
followed  by  the  expression  of the  EBV-determined  nuclear  antigen  (EBNA; 
reference 4), cellular DNA synthesis with blast transformation and induction of 
Ig secretion (5). 
Titration  experiments have shown that only ~20%  of in vitro EBV-infected 
peripheral  blood  B  lymphocytes express  EBNA  (6).  Several  publications have 
reported attempts to characterize the EBV-susceptible subpopulation of B lym- 
phocytes. The virus receptor is closely associated with the B  lymphocyte C3d- 
receptor (7, 8). Using density gradient fractionation, Robinsson et al. (9) showed 
that EBV induced DNA synthesis only in B lymphocytes of high to intermediate 
density, but these authors did not study the EBNA expression.  Einhorn et ai. 
(10) reported that activation of B cells with protein A inhibited the transforma- 
tion  of B  lymphocytes. According to  these  reports,  the virus-susceptible sub- 
population probably  corresponds to the small resting C3d-receptor positive B 
cells. 
EBV-transformed lymphoblastoid cell lines of nonneoplastic origin (LCL) have 
normal diploid karyotype (11). Such lines are polyclonal and their cells variable 
in size, morphology, and Ig expression (12).  In contrast, cell lines derived from 
BL tissues are monoclonal and never have a normal diploid karyotype. In virtually 
all  histologically proven cases,  they were found to carry one of three specific 
chromosomal translocations, the 8; 14 or the variants 8;2 or 8;22 (13). The cells 
are highly uniform, although different cell lines can differ (12). Both tumor and 
normally derived cell lines consists of large blastoid cells, but the morphology 
and  differentiation  marker  expression  shows  a  number  of  differences.  The 
membrane glycoprotein pattern expressed by LCL is similar to mitogen-activated 
mature normal B lymphoblasts, whereas tumor lines exhibit a pattern comparable 
to small  resting  B  lymphocytes (14).  The  LCL cells often express  mIgD and 
secrete Ig at a  high rate,  whereas the BL lines with few exceptions are m-lgD 
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negative and have a  very low Ig secretion (15). It is therefore believed that BL 
cells represent an immature stage of B cell development compared with the LCL. 
The susceptibility of the different B cell subpopulations to EBV is still an open 
question. We have used density gradient fractionation to further investigate the 
problem.  The  expression  of  the  EBNA  was  assessed  as  a  marker  for  viral 
transformation. Virus binding and penetration were assayed by using fluorescein- 
and radio-labeled virus preparations. We have also examined the density gradient 
distribution  profiles  of two  EBV-negative  BL  lines  and  their  EBV-converted 
sublines  in  the  comparison  with  the  density of normal  B  lymphocytes during 
transformation in vitro. 
Materials and Methods 
Cell Separations.  Mononuclear cells were obtained from huffy coat by Ficoll-Isopaque 
centrifugation (16), washed,  and  incubated with carbonyl iron for  1 h  at  37°C.  Iron- 
ingesting cells were removed with a magnet. To separate T  and B lymphocytes, the cells 
were mixed with 5% sheep erythrocytes (SE) in 20% newborn calf serum (NCS) and 3% 
dextran T70 (Pharmacia, Uppsala, Sweden) to form rosettes. After 45 min on ice, the 
rosetting and nonrosetting cells were separated on Ficoll-Isopaque gradient centrifugation 
(17). The nonrosetting B lymphocyte fraction was incubated for  1-2 h  in flatly laying 
tissue culture bottles to remove adherent cells. 
Cells from tonsils were prepared by mincing the tissue through a fine metal mesh. B 
cells were purified from the cell suspension as described for the blood mononuclear cells. 
Density-gradient Separations.  An isotonic stock of Percoli (Pharmacia) was prepared by 
mixing nine parts of Percoll with one part  10-fold concentrated buffered salt solution 
(BSS) (1.2 mM CaCl~, 138 mM NaCI, 5.4 mM KCI,  8.1  mM MgSO4,  0.5 mM KHPO4, 
0.3 mM NaPO4, pH 6.9) and adjusting the osmolarity with 9% NaCI or water. This stock 
solution was mixed with BSS to 65.0%, 60.0%, 55.0%, 52.5, 50.0%, 47.5%, 45.0%, 42.5, 
and 40.0% Percoll. 1.5-ml portions of the nine solutions were layered over each other 
with decreasing density in a 15-ml tube to form noncontinuous nine-step gradients. Three- 
step gradients were prepared in a similar way using 3-ml volumes of 65.0%, 52.5%, and 
42.5%  Percoll solutions. The cells were suspended in  1 ml fetal calf serum (FCS)  and 
layered on the top of the gradient. The gradient was centrifuged for 30 min at 800 g in 
a cooled swing-out rotor and the cell bands were collected with a pasteur pipette. 
Activation  of B  Cells.  Purified B cells  were cultured in anti-IgM-coated plastic petri 
dishes for 80 h  in medium with  10% FCS and 30% supernatant of pokeweed mitogen 
(PWM)-stimulated T  cell cultures (18). 
Cell Lines.  The  Ramos  and  BJAB  lines  have  been  established  from  EBV-negative 
lymphomas (19,  20).  Two in vitro EBV-converted Ramos sublines,  EHRA-Ramos (19) 
and Ramos-HR1K (21), and two converted BJAB lines, BJAB HR1K (21) and BJAB B95- 
8 (21), were also tested. The cell lines were resuspended every 3 or 4 d in tissue medium 
to a density of 0.2-0.3 million cells/ml. RPMI  1640 supplemented with  10% FCS and 
100 U penicillin and 100 #g streptomycin/ml were used for all cultures. 
Virus.  Virus was prepared by concentrating 4 ! of supernatant of the virus-producing 
B95-8 cells 400 times by centrifugation as described (22). The virus was stored frozen at 
minus 90 °C and diluted 1:20 in medium with 10% FCS before use. Further concentration 
of the virus did not increase the percentage EBNA-expressing cells in infected normal B 
lymphocytes or Ramos cells.  [3H]Thymidine-labeled virus was prepared after incubation 
of B95-8  cells  with  10  ttg/ml  of  12-O-tetradecanoyl-phorbol-13-acetate (TPA;  Sigma 
Chemical Co., St. Louis, MO) for 24 h to induce virus production (23). The cells were 
washed and incubated for 7 d at a starting density of 1 million/mi with 5 #Ci tritiated 
thymidine  per  ml.  The  supernatants  were  collected and  the  virus  was  purified  and 
concentrated as  described above.  Fluorescein  labeling of the  virus was  performed as 
described by Johnson et al.  (24).  Concentrated virus of the B95-8  (25) and  P3H (26) 
strains  were supplied  by  Life Sciences,  St.  Petersburg,  FL  (grant  provided by Shova 210  EPSTEIN-BARR  VIRUS  SUSCEPTIBILITY 
University Research Institute for Biomedicine in Florida). The virus was incubated with 
20  t~g fluorescein  per  mg virus  protein  at a  protein  concentration  of ~20  mg/ml  as 
determined by the Lowry method (27). The conjugation was performed at room temper- 
ature for 2.5 h. To separate the labeled virus from nonbound fluorescein, a Sephadex C 
25-M column (Pbarmacia) was used. The conjugates were stored at -90°C. 
Virus Infection.  The cells were pelletted at 350 g for 5 min and suspended in the virus 
solution at a density of 1 ×  106 cells/ml. Following incubation for 1 h at 37°C, the cells 
were washed and then resuspended in fresh medium at a density of 0.5 x  106 cells/ml. 
The virus binding assay and the assessment of [SH]thymidine-labeled viral DNA pene- 
tration was performed as described elsewhere (22).  Briefly, 200 ~1 of labeled virus was 
added to  1 x  10  6 cells and incubated for 2 h  at 37°C in a total volume of 1 ml BSS + 
10% FCS. The samples were split into two equal parts, for binding and penetration assay. 
The  cells  were  washed  three  times  and  the  bound  radioactivity was  determined.  To 
measure viral penetration  of the  plasma  membrane, the  ceils  were  washed  in  trypsin 
buffer (BSS without Ca  2+ and Mg  ~+) and resuspended in trypsin buffer with 0.25% trypsin. 
After  10  min of incubation at 37°C,  the cells were washed three times in BSS +  10% 
FCS, and the cell-bound radioactivity was determined.  The number of virus receptor- 
expressing cells was estimated by using fluorescein-labeled virus as described by Wells et 
al.  (28).  1 x  106 cells were incubated with  100 #1 of fluorescein-labeled virus diluted in 
BSS. After 30 rain of gentle shaking at room temperature, the cells were washed three 
times in BSS and resuspended in BSS-glycerol 1:1. The samples were examined in a Leitz 
Orthoplan  fluorescence  microscope at  1,000  times  magnification.  EBNA  staining  was 
performed  as  described  (29).  At  least  1,000  cells  of each  sample  were  counted  in  a 
fluorescence microscope at a  magnification of 500.  Control smears of all samples were 
stained with anti-EBNA-negative serum and smears from the EBNA-positive cell line Raji 
were stained and read in parallel as a positive control. 
Membrane  Mt~rker Staining.  Membrane Ig was detected by incubating 0.5  x  106 cells 
in  50 /A of fluorescein-conjugated  rabbit anti-human  IgM  +  IgG +  IgA  1:10  (DAKO 
Immunoglobulins, Copenhagen, Denmark) on ice for 1 h. The cells were washed twice in 
BSS, resuspended in BSS-glycerol 1:1, and counted in a fluorescence microscope. 
Staining with the pan-B-cell-reacting monoclonal antibody B1  (30) was performed by 
a  two-step method.  0.5  x  106  cells were  suspended  with  the  antibody at appropriate 
dilutions  and  incubated  on  ice  for  30  rain.  The  cells  were  washed,  incubated  with 
fluorescein-labeled rabbit anti-mouse Ig, and diluted  1:10 in BSS with 10% human serum 
on ice for 30 min. After a second wash the cells were resuspended in BSS-glycerol 1:1 for 
immunofluorescence examination.  Controls  were incubated  with  BSS  followed by the 
second antibody.  All  membrane fluoresence  stained  samples were  examined at  1,000 
times magnification in the Leitz fluorescence microscope. 
Results 
All  B  lymphocyte-enriched  preparations  were  checked  for SE  rosetting and 
tested  for  membrane  Ig  and  B1  expression.  Blood-derived  preparations  con- 
tained  1-2% SE rosetting,  85-95%  mIg-positive, and 90-95%  Bl-positive cells. 
Tonsil B cell preparations contained <0.5%  SE rosetting cells and >95%  mem- 
brane Ig-positive cells.  Likewise, >95% of these cells were Bl-positive. 
The  density  distribution  of  four  purified  peripheral  blood  B  lymphocyte 
samples is shown  in  Fig.  1.  Bl-negative  cells were enriched  in  the  low density 
fractions (Table  I). Blood-derived samples contained  between  10 and  35%  B1- 
negative  cells  in  the  low  density  fraction  9.  In  the  tonsil-derived  samples the 
number of Bl-negative cells were below 5%  in all fractions.  Only B  cell prepa- 
rations containing >75%  Bl-positive cells in each fraction were used for experi- 
ments. 
In  order  to  test  the  EBV  susceptibility,  the  cells  from  each  fraction  were /~.MAN ET  AL.  211 
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FIGURE  1.  Distribution of human B lymphocytes in density gradients. Purified human blood 
or tonsil B lymphocytes were fractionated on nine-step density gradients and the cell number 
in each fraction was counted. The results are presented as the percentage of cells in each 
fraction of the total number recovered cells. Density is decreasing from 1 to 9. (A) Distribution 
of four samples of purified blood B lymphocytes. (B) Distribution of four samples of purified 
tonsil B lymphoeytes. 
TABLE  I 
Reactivity with the B I Monoclonal Antibody in Fractionated Purified B 
Lymphocytes 
Fractions 
Percentage fluorescent cells and standard 
deviation 
Blood B lymphocytes  Tonsil B lymphocytes 
(n =  8)  (n =  4) 
9  82+6  94+4 
8  86±4  94__.4 
7  84±4  96+2 
6  92 + 5  98 _  2 
5  94 ± 2  99 + 0 
4  96 + 2  >99 
3  >99  >99 
2  >99  >99 
1  >99  >99 
Purified blood or tonsil B lymphocytes were fractionated on nine-step 
density gradients.  The  cells from  each fraction were  stained with the 
monoclonal antibody B 1 and fluorescein-labeled  rabbit anti-mouse Ig. The 
samples were then examined in fluorescence microscope and at least 500 
cells from each sample were counted. Density decreases from 1 to 9. 
collected, washed, and incubated with the B95-8 strain virus. The  percentage of 
EDNA-expressing cells were counted  after 48  h  (Table II). EDNA-positive cells 
were found  in the high density fractions  1-4  with some variations between  the 
donors. The  infectibility was confined to high density lymphocytes, as in earlier 
studies by Robinsson et al. (10) using DNA  synthesis as the measure of successful 
EBV infection. 
In all subsequent  experiments,  three-step gradients were used.  The  first step 
corresponded  to the first four fractions in the nine-step gradient and the second 
and third steps to fractions 5-7  and  8-9,  respectively. In order  to examine  the 212  EPSTEIN-BARR VIRUS  SUSCEPTIBILITY 
TABLE  II 
Frequency of EBNA-positive Cells in Different Percoll Fractions 48 h 
after EBV Infection 
Fractions  Donor A  Donor B  Donor C  Donor D 
9  0  0  0  0 
8  0  0  0  0 
7  0  0  0  0 
6  0  0  0  0 
5  0  0  0  0 
4  2.0  0  0.2  0 
3  2.4  8.0  0.5  0 
2  6.1  2.0  0  1.4 
1  6.1  1.1  3.0  3.4 
Un~actionated  4.9  4.8  5.2  4.0 
Purified human B lymphocytes from four donors were fractionated on 
nine-step Percoll gradients.  Each fraction  was  incubated  with (B95-8 
substrain) EBV for 48 h before staining for EBNA. The EBV-negative  cell 
line Ramos was used as a control of the infection and  showed 13.5% 
EBNA-positive  cells. At least 2 x l0  s cells from each sample were counted. 
Density decreases from 1 to 9. 
possibility that the different infectibility of the various fractions might be deter- 
mined  at  the  receptor  level,  they  were  tested  for  virus  using  fluorescein  or 
[ZH]thymidine-labeled virus. Cell preparations pooled from five different blood 
donors or from tonsils were fractionated on three-step  Percoll gradients.  The 
fractions were exposed to labeled or nonlabeled virus to test virus binding and 
penetration after 2 h  and EBNA expression after 60 h  of incubation. Although 
certain differences were noticed in the frequency of EBV membrane fluorescence 
(EMF)-positive cells between different fractions, they were relatively modest and 
their  significance  is  questionable  (Table  III).  Similar  results  were seen  in  the 
tested tonsil samples. 
Binding tests with tritiated methyl-thymidine-labeled virus showed that frac- 
tions 2 and 3  bound more virus than did fraction  1.  Since fraction  1 contained 
between 36 and 23% EBNA-positive cells and fractions 2 and 3 contained little 
or  no  EBNA-positive  cells,  these  results  indicate  that  the  presence  of  virus 
receptors on the membrane was not sufficient for transformation.  In order to 
test whether the differences in EBNA expression could be explained by resistance 
to virus penetration of the plasma  membrane in  the  low density fractions,  we 
tested the uptake of labeled virus-DNA into the cells. The cells were incubated 
with  [3H]thymidine-labeled  virus  for  2  h  at  37°C,  washed,  trypsinated,  and 
washed again to remove membrane-bound virus.  The radioactivity in the cells 
was determined.  Different incubation times with trypsin were tested. After  10 
min of trypsination, no more radioactivity could be removed from the cells. The 
viability of the cells decreased after 15 min with trypsin. 10 min trypsination was 
therefore used in all experiments. 
Our studies of density-fractionated lymphocytes showed that the virus pene- 
tration into fraction 2 cells was equal or slightly higher than into fraction 1, and 
the penetration  of fraction 3  cells was clearly higher than  into fraction  1 cells 
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TABLE  III 
EBV Binding to and Penetration into B Cell Populations Fractionated on Three-step Density 
Gradients 
Percent- 
Per-  Binding of  age 
Sample  Fraction  centage  [SH]thymi-  Virus penetration  EBNA- 
EMF-  dine-  positive 
density  positive  labeled  of the cells  cells 60 h 
cells  virus  after in- 
fection 
cpm  cpm  %  % 
Peripheral blood B lym-  High  65  43 
phocytes 
Intermediate  69  <I 
Low  80  0 
Tonsil B lymphocytes  High  66  5,337  4,750  90  36 
Intermediate  62  7,098  4,860  68  3 
Low  71  9,622  6,000  62  0 
Tonsil B lymphocytes  High  69  4,899  4,063  83  23 
Intermediate  68  5,232  4,247  81  0 
Low  72  5,107  3,989  78  0 
Controls  Raft  60  9,842  3,660  37 
P3H  0  889  568  63 
Purified B lymphocytes from tonsils, or pooled from five blood donors, were fractionated on three- 
step density gradients into high, intermediate, and  low density subpopulations.  The virus binding 
was tested with fluorescein- and [SH]thymidine-labeled virus and the results presented as percentage 
EBV-membrane fluorescence (EMF) positive cells, or as cell-bound radioactivity (cpm). Penetration 
of viral DNA into the cells were estimated using [3H]thymidine-labeled virus and results are presented 
as cpm or percentage uptake of total bound radioactivity. The cells were incubated with 50,000 cpm 
radioactive virus. Cells infected in parallel were stained for EBNA 60 h after infection. At least 1,000 
cells were  counted  for each  sample.  The  EBV  receptor-positive cell line  Raji and  the  receptor 
negative cell line P3H were used as controls. Experiments using labeled P3H or B95-8 virus gave 
identical results. 
to the cells, showed however that whereas 83-90% of the bound virus penetrated 
fraction  1 cells,  68-81%  and  62-78%  of the virus DNA was found inside the 
cells. The resistance to EBV-transformation in fractions 2 and 3 could therefore 
not  be  explained  by  different  virus  binding  or  virus  penetration  into  these 
subpopulations. 
The density of B cells decreases upon activation.  It was therefore likely that 
the low density fractions represented activated B cells. Following this hypothesis, 
we have tested the infectibility of activated B cell populations. Tonsil-derived B 
lymphocytes were activated by culturing in petri dishes coated with rabbit anti- 
human  IgM in the presence of 30% supernatant  from PWM-stimulated 3-d-old 
T  cell cultures. Controls were cultured in petri dishes without antibodies and T 
cell supernatants,  or kept at 4°C. After 80 h,  the cell suspensions were cleared 
of debris  and  dead  cells  by  Ficoll-Isopaque  centrifugation  and  subsequently 
fractionated  on  Percoll  gradients.  Both  the  antibody-stimulated  and  control 
cultured  cells  were  distributed  mainly  in  the  low  and  intermediate  density 
fractions.  The  majority of the  stimulated  cells were found  in  the  low density 
fraction 3, while the control cultures were found mainly in fraction 2. The cells 
kept at 4°C showed a pattern similar to that of the original cell preparation. 214  EPSTEIN-BARR VIRUS SUSCEPTIBILITY 
Cells infected without prior cultivation became EBNA positive with a frequency 
of 10-26% (Table IV). In contrast, no EBNA-positive cells were found either in 
the  stimulated or in  the control  cultures  infected after 80  h  in  vitro culture. 
Infection after 80  h  at 4°C in culture medium induced 4-11%  EBNA-positive 
cells. The subsequent proliferation intensity and survival of the cultures was in 
line with the EBNA staining. EBNA-positive cells grew out only from the directly 
infected cells and from cells stored 80 h in a refrigerator. 
EBV transformation of normal B lymphocytes leads to polyclonal cell activa- 
tion,  blast  transformation, and  in addition, prolonged  persistence of EBV  ge- 
nomes to expression of EBNA and possibly other viral products as well. If one 
wishes to dissociate the effects of EBV in inducing blast transformation from the 
phenotypic effects due to persistence of the viral genome and presence of the 
nuclear antigen,  EBV-negative  B  lymphoma lines and their in vitro EBV-con- 
verted  sublines  are  useful,  since  they  represent  the  same  clone  of immortal 
neoplastic blast cells that only differ from each other with regard to the presence 
of EBV-DNA and EBNA in the converted lines. 
Previously, such comparisons have detected differences between the negative 
lines  and  their  derived  EBNA-positive  sublines,  with  regard  to  sensitivity to 
saturation  density  (31),  serum  requirements,  capping  properties  (32),  lectin 
agglutinability (33),  membrane  IgD,  and insulin receptor  expression  (34).  No 
difference in density was seen, however, between EBNA-positive and -negative 
lines. In addition to these lines, we have also tested 16 EBV-carrying cell lines. 5 
of these were lymphoblastoid lines (LCL) of normal origin, whereas 11 were BL 
lines. All established lines showed similar density distribution, restricted to the 
low density part of the gradient, i.e. fractions 6 to 9. 
In view of the fact that the target cells of the transformation were only seen 
in the high to intermediate density fractions, we have examined the density of 
the EBNA-positive cells shortly after infection. 
Purified B  cells were fractionated on three-step  gradients and the separated 
high intermediate and low density cells were infected with the B95-8  substrain 
of EBV. The cells were incubated at 37 °C for 48 h  and each fraction was once 
again fractionated on a  three-step Percoll gradient. The fractionated cells were 
TABLE  IV 
Frequency of EBNA-positive Cells in Directly Infected vs. Preincubated B 
Lymphocytes 
Medium supplement during pre- 
Precuhure  culture 
Percent EBNA-positive 
cells 
Donor  Donor  Donor 
1  2  3 
None  --  10  23  26 
80 h at 37°C  Anti-e-serum  + T cell factors  0  0  0 
80 h at 37°C  None  0  0  0 
80 h at 4 °C  None  4  5  11 
B lymphocytes  were purified from tonsils  and infected with EBV directly or after 
cultivation as indicated. The cells were harvested for EBNA staining 48 h after 
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collected,  washed,  counted,  and  stained  for EBNA.  Samples  from all fractions 
were also taken for further cultivation.  As shown in Fig. 2, 73-83%  of the high 
density population had shifted to intermediate density and 3-8% had shifted to 
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FmURE  2.  Distribution of human blood B lymphocytes in three-step density gradients before 
and after 40 h of incubation. (A) Distribution of four freshly prepared samples. (B) Distribution 
of the cells in each fraction after EBV B95-8 substrain infection and subsequent incubation 
for 48 h at 37 °C. {C) Distribution of high density controls cultured 48 h at 37 °C without EBV. 
The figure shows the mean percentage of cells in high density, intermediate, and low density 
fractions. Standard deviation is indicated. 
TABLE  V 
Percentage EBNA-positive Cells 48 h after the EBV Infection of B Lymphocytes 
of Different Densities 
EBV-infected  Density fraction at  Percentage EBNA-positive cells 
density fraction  harvest for EBNA  Donor  Donor  Donor  Donor 
staining  A  B  C  D 
High  0  0  0  0 
High  Intermediate  16  14  ! 3  18 
Low  0  1  3  0 
Unfractionated  12  9  11  9 
Intermediate  Unfractionated  0  0  0  0 
Low  Unfractionated  0  0  0  0 
Purified  B  cells from  blood were  fractionated on three-step density gradients 
before and 48  h  after EBV infection.  Frequency of EBNA-producing cells in 
each fraction was determined. At least 1,000 cells from each sample were counted 
in immunofluorescence microscope. The EBV-negative lymphoma cell line Ra- 
mos was infected as a control. 24% of the Ramos cells were EBNA-positive 48 h 
after infection. Donors and fractions as in Fig. 2. 216  EPSTEIN-BARR VIRUS SUSCEPTIBILITY 
TABLE  VI 
EBNA Production in EBV-infected Purified High Density B 
Lymphocytes Density Fractionated 9 h after Infection 
Density fractions  Donor 1  Donor 2  Donor 3 
High  0  0  0 
Intermediate  43  29  62 
Unfractionated  14  16  19 
High density B lymphocytes  were purified from tonsils, infected with EBV, 
and incubated for 9 h before density fractionation on three-step gradients. 
The high and intermediate density cells were incubated for 40 h more, 
harvested, and stained for EBNA. No cells were found in the low density 
part of the gradient. At least 1,000 cells from each sample were counted 
in an immunofluorescence  microscope. The EBV-negative  cell line Ramos 
was control-infected and found to contain 18% EBNA-positive  cells 50 h 
after infection. 
(Fig. 2 C). The intermediate and low density cells were more stable and showed 
only minor changes in their gradient distribution. 
Table V shows the occurrence of EBNA-positive cells in the different subpop- 
ulations. Between 8 and 14% EBNA-positive cells were found in the initial high 
density population. The other populations remained negative. In the high density 
population, between  13 and  18%  of the cells that had shifted to intermediate 
density and  0-3%  of the  cells  that  shifted to  low density were  found EBNA 
positive.  In  contrast,  no  EBNA-positive  cells  remained  at  high  density.  The 
subsequent  proliferation  history  of the  cultures  was  in  line  with  the  EBNA 
positivity.  Proliferating cells  were  only seen  in  the samples  where  EBNA  was 
detected, even when the observation period  was extended to several  weeks of 
incubation and  nursing.  These  results showed that  the EBNA  expression  was 
associated with a shift to lower density and that high density cells never expressed 
EBNA.  In  order  to  further  investigate sequences  of density shift and  EBNA 
expression, we purified high density tonsil B lymphocytes, infected the cells with 
B95-8  strain  of EBV,  and  incubated  for  9  h  at  37°C.  The  cells  were  again 
fractionated into high, intermediate, and low density fractions and each fraction 
was incubated further for 40 h at 37 °C before harvesting and staining for EBNA. 
The results show that only cells that had shifted from  high to intermediate 
density 9 h after infection, later produced EBNA (Table VI). EBNA was reported 
to be produced at the earliest,  12  h  after infection (5).  Taken together, these 
results  indicated that only cells that have changed from  high to intermediate 
density within 9 h after infection, were later induced to EBNA expression. Thus, 
the  cells  had  changed  their  density  at  least  3  h  before  the  onset  of EBNA 
production. 
Discussion 
It is well known that EBV can only infect and transform a  subpopulation of 
human  B  lymphocytes, but  the  characteristics  of this  subpopulation  have  not 
been established. New separation methods have allowed a fractionation of B cell 
populations that permits a  detailed study of this problem.  In the present study 
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could then study the susceptibility of B cells of different density to EBV infection, 
as judged by EBNA synthesis and subsequent outgrowth of lines. We have also 
studied changes in cellular density that occurred in the course of EBV transfor- 
mation. Three subpopulations of human blood and tonsil B lymphocytes were 
studied  regarding  their  susceptibility  to  EBV:  the  high  density fractions are 
enriched for small resting B cells (35, 36, ,~man et al., unpublished observations). 
In the mouse system they have been described as Go cells, and both mouse and 
human  high  density B  cells  respond  poorly to  mitogens as judged  by  DNA 
synthesis (35,  36).  Intermediate density cells were characterized in  the mouse 
system as G1  cells. They give a  strong DNA synthesis response after mitogen 
stimulation.  The  low  density population  is  enriched for large activated cells. 
Some of them are already in the S-phase, as indicated by a  spontaneous DNA 
synthesis (Aman et al., in preparation). The three density fractions also showed 
differences in expression of several B cell differentiation markers detected by 
monocional antibodies. 
Our results showed that ony cells in the high density fractions could be infected 
with EBV as indicated by EBNA synthesis. All fractions contained >60%  EBV 
receptor-positive cells and the virus penetrated cells from all the fractions. The 
small variations in EBV receptor-expressing cells and virus penetration of the 
plasma membrane could not explain the striking differences in EBNA producers 
seen after infection. Since Bl-negative cells were enriched in  the low density 
part of the gradient (Table I), the question arises whether these cells could have 
inhibited the EBV infection. This is unlikely, however, since intermediate and 
low density fractions from tonsils contained no or few B 1-negative cells and still 
were resistant to  EBV transformation. Our results,  therefore strongly suggest 
that only resting B lymphocytes  can be infected by EBV. This is further supported 
by the results presented in  Table  IV,  showing that T  cells and  macrophage- 
independent activation of B cells prevented their infectibility. 
We also found that in vitro cultivation leads to a decrease in density and blocks 
the EBV susceptibility itself. This density shift does not appear to be an osmotic 
artefact due to hypotonicity of the medium or its relatively low protein content, 
since  the  process  is  inhibited  at  4°C.  Moreover,  monoclonal  B  lymphocyte 
populations from chronic lymphocytic leukemia patients remained stable at high 
density during several days of in vitro cultivation (Aman et al., in preparation). 
If it is accepted that the changes in density are due to activation, a number of 
alternatives can be  considered as possible  explanations  for this  phenomenon. 
Several  factors  may  be  considered  as  being  potentially  responsible  for  this 
spontaneous  density  shift.  It  could  represent  an  in  vitro  continuation  to  a 
maturation  process  that  may  have  started  already  in  vivo.  It  might  reflect 
nonspecific activation that may occur during preparation of the B cells, and it 
could be due to the heterologous serum component in the medium. The latter 
possibility  has  been  excluded by  results  from experiments made  in  10-30% 
autologous serum.  In  other experiments we have found that  the majority of 
nonstimulated B cells during the first 24 h of cultivation express transiently the 
activation markers BB1  and LB1  (37).  This is in contrast with the anti-Ig +  T 
cell  supernatant  stimulated  cells  that  show  a  stable  expression  of the  same 
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The exclusive susceptibility of the heavy resting B cells to the EBV transfor- 
mation contrasts with the low density of the EBV-transformed cell lines. Short- 
term experiments showed that the density shift precedes the EBNA production. 
This can be interpreted in two ways. The virus may infect only the very small 
population that is in the process of the activation/maturation-like event detected 
as  a  density  shift,  or  the  virus  infects  also  other  cells  but  the  spontaneous 
activation-density decrease  of the  cells  is  necessary for  initiation of the  viral 
activity inside the cell.  Further investigations of early events during activation 
and EBV transformation will show which alternative is right. 
Summary 
Human blood and tonsil B lymphocytes were fractionated on density gradients 
and tested for virus binding and penetration into the cells.  Epstein-Barr Virus 
(EBV)  transformation was detected by immunofluorescence staining for EBV- 
determined nuclear antigen (EBNA).  EBV bound to and penetrated all B cell 
populations, but only the high density populations were transformed. Activated 
B  lymphocytes were  found in  the  low  density fractions and  these  cells  were 
resistant to EBV infection. 
Infected and noninfected B lymphocytes were density-analyzed during in vitro 
culture. A spontaneous, not virus-induced, density decrease was found to precede 
the production of EBNA. Cells remaining at high density never expressed EBNA. 
The results suggest that EBV can transform only small resting B lymphocytes 
and that a virus-independent activation of the infected cells induces the EBNA 
production and transformation. 
Received  for publication I August 1983. 
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